Published on
November 3, 2025
- 11:30 GMT
First Patient Treated with BioVentrix® Revivent System in RELIVE Trial at Saint Luke’s Mid America Heart Institute
Pivotal RELIVE Trial Is Evaluating the Safety and Efficacy of BioVentrix’s Revivent System in the Treatment of Patients Who Have Experienced Heart Failure MANSFIELD, MA, UNITED STATES, November 3, 2025 /EINPresswire.com/ -- BioVentrix, Inc., a private …
Distribution channels:
Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry
...
